MTFB News and Press, Motif Bio plc From 06/06/19

NEW YORK, June 06, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has received the official minutes of the Type A meeting the Company held with the U.S. Food...

NEW YORK, May 31, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announces that at the Annual General Meeting held earlier today, all but one of the resolutions proposed were duly passed by ...

NEW YORK, May 22, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announces that at the Company’s AGM held earlier today the Company provided the following review of key aspects of its...

Motif Bio (NASDAQ: MTFB ) has signed an agreement with Otto-von-Guericke University Magdeburg to conduct a study evaluating iclaprim in an in vitro model of ocular toxoplasmosis. More news on: Motif Bio plc, Healthcare stocks news, Stocks on the move, Read more ...

NEW YORK, May 22, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has signed an agreement with Otto-von-Guericke University Magdeburg to conduct a study evalu...

NEW YORK, May 21, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that three iclaprim abstracts have been accepted for presentation at the upcoming American Society For Microb...

Catalyst Pharmaceuticals ( CPRX ) - As I'm writing this, the stock has lost 40% of its value in a single day after news came that the FDA approved Ruzurgi from Jacobus Pharma for LEMS (Lambert-Eaton myasthenic syndrome) patients age six to less than 17 years of age. This is the first app...

NEW YORK, May 03, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, confirms that the Company met with the U.S. Food & Drug Administration (FDA) on May 3, 2019 as expected. The Type A meeti...

Staffing 360 Solutions (NASDAQ: STAF ) +22%  on Q1 earnings . More news on: Staffing 360 Solutions, Inc., Nu Skin Enterprises, Inc., Enphase Energy, Inc., Stocks on the move, Read more ...

NEW YORK, May 01, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has signed an agreement with Lamellar Biomedical Limited (Lamellar) under which Motif Bio wi...